Phosphodiesterase type 5 inhibitors usage and prostate cancer : a match-paired analysis

Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PD...

Full description

Bibliographic Details
Published in:Translational andrology and urology, Vol. 6, No. 5 (2017), p. 879-882
Main Author: Machen, G Luke
Other Involved Persons: Rajab, M Hasan ; Pruszynski, Jessica ; Coffield, K Scott
Format: electronic Article
Language:English
ISSN:2223-4691
Item Description:Date Revised 13.11.2018
published: Print
Citation Status PubMed-not-MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.21037/tau.2017.06.02
Subjects:
QR Code: Show QR Code